Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03297606 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Study acronym: CAPTUR
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 59 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv59
  2. Primary completion date: Jan 31, 2026 to Dec 31, 2026v58
  3. Re-verified, no change to tracked fieldsv57
  4. Study sites revised (10)v56
  5. Study sites revised (10)v55
Show 45 earlier versionsHide 45 earlier versions
  1. Site details revised at 2 of 10 sitesv54
  2. 3 versions Re-verified since Jul 17, 2024, no change to tracked fieldsv51-v53
  3. Study sites revised (10)v50
  4. 3 versions Re-verified since Mar 28, 2024, no change to tracked fieldsv47-v49
  5. Site details revised at 1 of 10 sitesv46
  6. Site details revised at 1 of 10 sitesv45
  7. 2 versions Re-verified since Dec 11, 2023, no change to tracked fieldsv43-v44
  8. Site details revised at 2 of 10 sitesv42
  9. Start date: Oct 6, 2017 to Mar 23, 2018v41
  10. Site details revised at 1 of 10 sitesv40
  11. Site details revised at 1 of 10 sitesv39
  12. Site details revised at 1 of 10 sitesv38
  13. Site contacts updated at 1 of 10 sitesv37
  14. Site details revised at 1 of 10 sitesv36
  15. Re-verified, no change to tracked fieldsv35
  16. Primary completion date: Jun 30, 2023 to Jan 31, 2026
    • Study completion date: Sep 30, 2023 to Jan 31, 2027
    • Site details revised at 1 of 10 sites
    v34
  17. Site details revised at 2 of 10 sitesv33
  18. Primary completion date: Sep 30, 2022 to Jun 30, 2023v32
  19. Interventions: Axitinib (Drug), Bosutinib (Drug), Crizotinib (Drug), Dasatinib (Drug), Erlotinib (Drug), Nivolumab plus Ipilimumab (Drug), Olaparib… to Axitinib (Drug), Bosutinib (Drug), Crizotinib (Drug), Dasatinib (Drug), Erlotinib (Drug), Nivolumab plus Ipilimumab (Drug), Olaparib…
    • Site details revised at 1 of 10 sites
    • Collaborators: 4 to 5
    • Study arms: 13 to 14
    v31
  20. Re-verified, no change to tracked fieldsv30
  21. Site details revised at 1 of 10 sitesv29
  22. Site details revised at 1 of 10 sitesv28
  23. 2 versions Re-verified since Mar 14, 2022, no change to tracked fieldsv26-v27
  24. Site details revised at 1 of 10 sitesv25
  25. Re-verified, no change to tracked fieldsv24
  26. Primary completion date: Sep 2021 to Sep 30, 2022
    • Study completion date: Sep 2021 to Sep 30, 2023
    • Site details revised at 1 of 10 sites
    v23
  27. Study sites: 9 to 10v22
  28. Eligibility criteria expanded, about 11 wordsv21
  29. Study sites: 8 to 9v20
  30. Site details revised at 2 of 8 sitesv19
  31. Site details revised at 1 of 8 sitesv18
  32. Re-verified, no change to tracked fieldsv17
  33. Study sites: 7 to 8v16
  34. Eligibility criteria expanded, about 26 wordsv15
  35. Eligibility criteria shortened, about 97 words
    • Secondary endpoints revised (2)
    • Study description shortened, about 19 words
    v14
  36. Study sites: 6 to 7v13
  37. Study sites: 5 to 6v12
  38. Re-verified, no change to tracked fieldsv11
  39. Site contacts updated at 1 of 5 sitesv10
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.
Trial Details
NCT Number NCT03297606
Lead Sponsor Canadian Cancer Trials Group
Collaborators: AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Pfizer, Seagen Inc.
Conditions
(from sponsor)		 Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Related terms Lymphoma, Non-Hodgkin, Multiple Myeloma
Enrollment 720 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov